Protalix BioTherapeutics, Inc. (PLX) financial statements (2022 and earlier)

Company profile

Business Address 2 UNIVERSITY PLAZA
HACKENSACK, NJ 07601
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments38,985 17,79237,80851,16363,281
Cash and cash equivalents38,985 17,79237,80851,16363,281
Receivables3,442 4,7004,7291,721693
Inventory, net of allowances, customer advances and progress billings17,954 8,1558,5697,8335,245
Inventory17,954 8,1558,5697,8335,245
Disposal group, including discontinued operation     327
Other current assets1,285 1,8321,8771,9342,321
Total current assets:61,666 32,47952,98362,65171,867
Noncurrent Assets
Operating lease, right-of-use asset4,960 5,677
Property, plant and equipment4,962 5,2736,3907,6768,703
Defined benefit plan, assets for plan benefits1,677
Other undisclosed noncurrent assets2,077 1,9631,7581,887 
Total noncurrent assets:11,999 12,9138,1489,56310,380
TOTAL ASSETS:73,665 45,39261,13172,21482,247
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities16,433 11,90510,2749,3107,496
Accounts payable16,433 11,90510,2749,3107,496
Deferred revenue8,550 16,335
Debt  5,440 5,92153,872
Deferred revenue and credits 837
Contract with customer, liability9,868
Other undisclosed current liabilities8,193 6,4955,2117,5214,007
Total current liabilities:33,176 40,17525,35322,75266,212
Noncurrent Liabilities
Long-term debt and lease obligation32,263 55,48547,96646,26723,644
Long-term debt, excluding current maturities27,887 50,95747,96646,26723,644
Operating lease, liability4,376 4,528
Liabilities, other than long-term debt14,262 20,05440,69334,4882,348
Deferred revenue and credits26,851 
Deferred revenue11,790 16,980
Contract with customer, liability33,027
Liability, pension and other postretirement and postemployment benefits2,472 2,5652,3742,5862,348
Other liabilities  5095,2925,051 
Total noncurrent liabilities:46,525 75,53988,65980,75525,992
Total liabilities:79,701 115,714114,012103,50792,204
Stockholders' equity
Stockholders' equity attributable to parent(6,036) (70,322)(52,881)(31,293)(9,957)
Common stock46 15148144124
Additional paid in capital368,852 270,492269,524266,495202,575
Accumulated deficit(374,934) (340,829)(322,553)(297,932)(212,656)
Total stockholders' equity:(6,036) (70,322)(52,881)(31,293)(9,957)
TOTAL LIABILITIES AND EQUITY:73,665 45,39261,13172,21482,247

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Revenues38,350 54,693 19,2429,199
Cost of revenue(16,349) (10,895)(9,302)(15,231)(8,398)
Gross profit:22,001 43,798(9,302)4,011801
Operating expenses(42,463) (54,592)(46,450)(43,700)(39,768)
Other undisclosed operating income  7736,4443,3365,804
Operating loss:(20,462) (10,717)(19,308)(36,353)(33,163)
Nonoperating income (expense)(7,120) (7,559)(7,149)(48,923)3,987
Other nonoperating expense(7,120) (7,559)(7,149)(9,537)(10,076)
Interest and debt expense(831) (2,991)(2,602)(2,334)(568)
Loss from continuing operations:(28,413) (21,267)(29,059)(87,610)(29,744)
Loss from discontinued operations     (189)
Net loss:(28,413) (21,267)(29,059)(87,610)(29,933)
Other undisclosed net income attributable to parent831 2,9912,6022,334568
Net loss available to common stockholders, diluted:(27,582) (18,276)(26,457)(85,276)(29,365)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss:(28,413) (21,267)(29,059)(87,610)(29,933)
Comprehensive loss, net of tax, attributable to parent:(28,413) (21,267)(29,059)(87,610)(29,933)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: